Literature DB >> 20037200

Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.

Vincenzo N Talesa1, Cinzia Antognelli, Chiara Del Buono, Fabrizio Stracci, Maria R Serva, Emanuele Cottini, Ettore Mearini.   

Abstract

Prostate cancer (PCa) is a heterogeneous, multifactorial and multifocal disease. Therefore, the search for a combination of assays using a panel of tumor markers is fundamental for a more precise and reliable diagnosis. In the present study we investigated the diagnostic value of five different genes, associated with PCa carcinogenesis, encoding for prostate-specific membrane antigen (PSMA), serine protease Hepsin, PCa antigen 3 (PCA3), UDP-N-acetyl-alpha-D-galatosamine transferase (GalNAC-T3) and prostate-specific antigen (PSA). Forty-four patients, with previously untreated, histologically verified PCa and forty-six patients with benign prostatic hyperplasia (BPH) were enrolled in this study. Absolute concentration of the transcript levels of each gene was calculated by quantitative Real-Time PCR analysis in urine sediments of men suffering from PCa or BPH after prostatic massage. The diagnostic value of a concomitant examination of these markers was evaluated by logistic regression analysis. We demonstrated that the diagnostic potential of the combined urinary PSA and PSMA level was significantly better than that of each singularly considered marker, including total serum PSA, the present gold standard test for PCa diagnosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20037200     DOI: 10.3233/CBM-2009-0109

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  13 in total

Review 1.  An overview of prostate diseases and their characteristics specific to Asian men.

Authors:  Shu-Jie Xia; Di Cui; Qi Jiang
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

2.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

3.  Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.

Authors:  Milan Subedi; Il Minn; Jianbo Chen; YunHye Kim; Kiwon Ok; Yong Woo Jung; Martin G Pomper; Youngjoo Byun
Journal:  Eur J Med Chem       Date:  2016-04-14       Impact factor: 6.514

4.  Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4-10 ng/mL.

Authors:  Yongqiang Zhou; Yun Li; Xiangnan Li; Minjun Jiang
Journal:  Biomed Res Int       Date:  2017-02-15       Impact factor: 3.411

5.  High miR-31-5p expression promotes colon adenocarcinoma progression by targeting TNS1.

Authors:  Bobin Mi; Qiushi Li; Tong Li; Guohui Liu; Jiayang Sai
Journal:  Aging (Albany NY)       Date:  2020-04-21       Impact factor: 5.682

6.  Biomarkers in prostate cancer epidemiology.

Authors:  Mukesh Verma; Payal Patel; Mudit Verma
Journal:  Cancers (Basel)       Date:  2011-09-30       Impact factor: 6.639

7.  Glyoxalase 1-419C>A variant is associated with oxidative stress: implications in prostate cancer progression.

Authors:  Cinzia Antognelli; Letizia Mezzasoma; Ettore Mearini; Vincenzo Nicola Talesa
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

Review 8.  The present and future of prostate cancer urine biomarkers.

Authors:  Marina Rigau; Mireia Olivan; Marta Garcia; Tamara Sequeiros; Melania Montes; Eva Colás; Marta Llauradó; Jacques Planas; Inés de Torres; Juan Morote; Colin Cooper; Jaume Reventós; Jeremy Clark; Andreas Doll
Journal:  Int J Mol Sci       Date:  2013-06-17       Impact factor: 5.923

Review 9.  Urine markers and prostate cancer.

Authors:  Jacek Wilkosz; Magdalena Bryś; Waldemar Różański
Journal:  Cent European J Urol       Date:  2011-03-18

Review 10.  Glyoxalases in Urological Malignancies.

Authors:  Cinzia Antognelli; Vincenzo Nicola Talesa
Journal:  Int J Mol Sci       Date:  2018-01-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.